926 related articles for article (PubMed ID: 32853987)
1. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients.
Xiao Z; Nie K; Han T; Cheng L; Zhang Z; Peng W; Shi D
J Immunol Res; 2021; 2021():6439975. PubMed ID: 34541005
[TBL] [Abstract][Full Text] [Related]
4. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344
[TBL] [Abstract][Full Text] [Related]
7. A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
Zheng S; Luo X; Dong C; Zheng D; Xie J; Zhuge L; Sun Y; Chen H
Int J Cancer; 2018 Nov; 143(10):2592-2601. PubMed ID: 30152019
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
9. Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma.
Zhang C; Zhang Z; Sun N; Zhang Z; Zhang G; Wang F; Luo Y; Che Y; He J
Oncoimmunology; 2020 Sep; 9(1):1824641. PubMed ID: 33457102
[TBL] [Abstract][Full Text] [Related]
10. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance.
Wang QW; Lin WW; Zhu YJ
Cell Commun Signal; 2022 Jan; 20(1):6. PubMed ID: 35000592
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
13. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
Wang H; Wei C; Pan P; Yuan F; Cheng J
Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma.
Wang J; He L; Tang Y; Li D; Yang Y; Zeng Z
Aging (Albany NY); 2020 Nov; 12(22):23200-23216. PubMed ID: 33221751
[TBL] [Abstract][Full Text] [Related]
15. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
16. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
Wang Z; Chen X
Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
[TBL] [Abstract][Full Text] [Related]
17. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]